Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparing barriers to early stage diagnosis of hepatocellular carcinoma between safety net hospitals and academic medical centers: An analysis from the United States Safety-Net Collaborative.

Journal of surgical oncology·2024

Same author

Adjuvant therapy for stage IIB + IIC melanoma.

Journal of surgical oncology·2023

Same author

Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database.

Journal of surgical oncology·2023

Same author

Neoadjuvant therapy for melanoma: A critical appraisal.

Journal of surgical oncology·2022

Same author

Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: An US safety net collaborative analysis.

Journal of surgical oncology·2022

Same author

Adherence to guidelines at the patient- and hospital-levels is associated with improved overall survival in patients with gastric cancer.

Journal of surgical oncology·2022

Same journal

The Treatment Efficacy for Patients Undergoing Combined Transanal-Transabdominal Endoscopic Resection of Rectal Anastomosis Stenosis.

Journal of surgical oncology·2026

Same journal

"It Depends on the Situation": Variability in How Surgical Oncologists Elicit and Integrate Patient Values.

Journal of surgical oncology·2026

Same journal

A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion.

Journal of surgical oncology·2026

Same journal

How I Do It: The Life and Work of a Rubber Band in Robotic Liver Parenchymal Transection.

Journal of surgical oncology·2026

Same journal

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026

Same journal

Performance of Survival Prediction Tools in Patients With Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.

Journal of surgical oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 7, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Neoadjuvant immunotherapy for melanoma.

Ann Y Lee¹, Mary S Brady²

¹Department of Surgery, NYU Langone Health, New York, New York, USA.

Journal of Surgical Oncology

|October 1, 2020

Summary

This summary is machine-generated.

Neoadjuvant immunotherapy shows promise for high-risk resectable melanoma, building on successful adjuvant treatments. This review explores the evidence supporting its use before surgery for improved patient outcomes.

Keywords:

checkpoint blockade high risk immunotherapy melanoma neoadjuvant resectable

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Dec 7, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

Oncology
Immunology
Dermatology

Background:

Immunotherapy, particularly checkpoint blockade inhibitors, is effective for metastatic melanoma.
Adjuvant immunotherapy improves survival in high-risk resectable melanoma.
Early efficacy data fuels interest in neoadjuvant immunotherapy for this patient group.

Purpose of the Study:

To review the rationale for neoadjuvant immunotherapy in high-risk resectable melanoma.
To summarize current data supporting its use in the neoadjuvant setting.

Main Methods:

Literature review of clinical trials and relevant studies.
Analysis of data on neoadjuvant immunotherapy efficacy and safety.

Main Results:

Early studies indicate significant efficacy of neoadjuvant immunotherapy.
Potential for improved surgical outcomes and reduced recurrence.

Conclusions:

Neoadjuvant immunotherapy is a promising approach for high-risk resectable melanoma.
Further research and clinical trials are warranted to establish its role.